The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Cardiovascular Diabetology

Chien-Ying Huang¹  Cze-Ci Chan¹  Ann Wan-Chin Ling¹  Pao-Hsien Chu²  Yi-Hsin Chan³  Shao-Wei Chen⁴  Yi-Wei Kao⁵ 

[1] Cardiovascular Department, Chang Gung Memorial Hospital, 33305, Linkou, Taoyuan, Taiwan;Cardiovascular Department, Chang Gung Memorial Hospital, 33305, Linkou, Taoyuan, Taiwan;College of Medicine, Chang Gung University, 33302, Taoyuan, Taiwan;Cardiovascular Department, Chang Gung Memorial Hospital, 33305, Linkou, Taoyuan, Taiwan;College of Medicine, Chang Gung University, 33302, Taoyuan, Taiwan;Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan;Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan;Center for Big Data Analytics and Statistics, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan City, Taiwan;Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan;

关键词: Atrial fibrillation;    Type 2 diabetes mellitus;    Sodium glucose cotransporter-2 inhibitor;    Dipeptidyl peptidase-4 inhibitor;    Heart failure;   

DOI  :  10.1186/s12933-020-01162-w

来源: Springer

【 授权许可】

CC BY